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ABSTRACT
Pancreatic cancer (PC) is an aggressive disease with high mortality rates, 
however, there is no blood test for early detection and diagnosis of this disease. 
Several research groups have reported on metabolomics based clinical investigations 
to identify biomarkers of PC, however there is a lack of a centralized metabolite 
biomarker repository that can be used for meta-analysis and biomarker validation. 
Furthermore, since the incidence of PC is associated with metabolic syndrome and 
Type 2 diabetes mellitus (T2DM), there is a need to uncouple these common metabolic 
dysregulations that may otherwise diminish the clinical utility of metabolomic 
biosignatures. Here, we attempted to externally replicate proposed metabolite 
biomarkers of PC reported by several other groups in an independent group of PC 
subjects. Our study design included a T2DM cohort that was used as a non-cancer 
control and a separate cohort diagnosed with colorectal cancer (CRC), as a cancer 
disease control to eliminate possible generic biomarkers of cancer. We used targeted 
mass spectrometry for quantitation of literature-curated metabolite markers and 
identified a biomarker panel that discriminates between normal controls (NC) and 
PC patients with high accuracy. Further evaluation of our model with CRC, however, 
showed a drop in specificity for the PC biomarker panel. Taken together, our study 
underscores the need for a more robust study design for cancer biomarker studies so 
as to maximize the translational value and clinical implementation.
INTRODUCTION
In 2017 an estimated 53,670 people in the US will 
be diagnosed with pancreatic cancer (PC), and 43,090 
people will die from it [1]. These numbers underscore 
high disease-associated mortality. PC represents 90% of 
pancreatic neoplasms and is likely to become the second 
most deadly cancer by 2020 [2–4]. The majority of patients 
present with incurable disease, and the median survival for 
advanced or metastatic PC is less than 5% at 5 years [5]. 
                                                                Meta-Analysis
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While known risk factors include age, chronic pancreatitis, 
and Type 2 diabetes mellitus (T2DM), the disease, for 
the most part, progresses indolently. Additionally, several 
epidemiological variables, such as tobacco smoking and 
obesity, have been deemed to increase risk, however these 
are not specific to PC and hence cannot be used to define 
a high risk population for PC screening [6–8]. The only 
approved serum PC biomarker, CA19-9, is nonspecific and 
only elevated in advanced disease and hence has no role as 
a standalone marker [9], or for detection of early disease. 
Thus, there is a critical need to develop diagnostic and 
prognostic biomarkers with potential clinical utility. Despite 
extensive efforts towards development of biomarkers for PC 
[10–31], there is a paucity of a validated biomarker panel 
that is specific for PC [32–34].
Metabolomics methodology aims to identify 
and estimate the relative changes in the abundance of 
endogenous metabolites in health and disease, thus 
supporting the identification of biomarkers and potential 
targets for the development of new therapeutics [35–37]. 
Given the role of the pancreas as a major metabolic 
organ, it is reasonable to assume that the identification, 
characterization and validation of novel disease 
stratification criteria based on metabolic profiles offers 
a strategic advantage for PC research [38–47]. Although 
a number of independent groups have reported on blood 
based metabolomics biomarkers of PC, the lack of cross-
validation limits the clinical utility of these putative 
biosignatures. 
This study was designed to address two existing 
challenges in the field of biomarker research for 
PC. Firstly, a majority of PC patients report glucose 
intolerance or T2DM [48, 49]. The majority of the 
published PC biomarker studies, however, have not 
used a diabetic cohort to identify shared pathway 
dysregulations that would help obviate non-specific 
biomarkers upfront. Secondly, certain oncogenic 
processes, like inflammation, cachexia and oxidative 
stress, accompany most malignancies.  However, most 
cancer biomarker studies, rely on a case-control study 
design that does not account for these confounders [50]. 
Thus, in the absence of cancer disease control cohorts, 
it is difficult to select biomarkers that are specific for 
a given cancer type, much less in advance of disease 
diagnosis or in defining risk of developing the specific 
neoplasm. As such, determination of predictive value of a 
biomarker panel without ascertaining disease specificity 
and cross-validation, is likely to impact subsequent 
clinical implementation.
 Herein, we report a novel experimental evaluation 
of putative metabolite biomarkers for PC that were curated 
from an exhaustive literature survey. We used targeted 
mass spectrometry for relative quantification of common 
blood based metabolite markers of PC, found to overlap 
in independently conducted studies. Next, we evaluated 
the performance of this group of metabolites in control 
cohorts, including a colorectal cancer cohort (CRC) that 
was used as a cancer control cohort, and T2DM which 
was used as a non-cancer disease control cohort. Although, 
the constructed 10 metabolite panel provided a high 
accuracy classifier for delineating PC patients from NC 
(AUC = 0.99), the AUCs still remained high when NCs 
were compared to the CRC cohort, thus diminishing the 
specificity of this panel for PC. Interestingly, the overlap 
of dysregulated metabolites between the PC and T2DM 
cohorts was lower than that observed for PC vs CRC 
cohorts. Taken together, our results emphasize the need 
for a more rigorous prospective study design that may 
help eliminate non-specific metabolite markers upfront, 
thereby augmenting the development of classifiers with 
high specificity for a particular malignancy.  The approach 
described here is broadly applicable for cancer biomarker 
studies.
RESULTS
Literature mining for delineating biomarkers  
of PC 
Since there is no central biomarker repository that 
can be accessed for metabolite biomarker evaluation of 
PC, our first goal was to perform an exhaustive literature 
search to create a compendium of metabolite biomarkers 
of PC [14]. While there are a large number of reported 
studies for PC biomarkers (a keyword search for 
“pancreatic cancer and biomarkers” in PUBMED returns 
> 9500 published articles); narrowing the search with 
specific keywords such as “metabolomics and pancreatic 
cancer biomarkers”, returned approximately 44 hits on 
PUBMED. We also looked in data repositories such as 
EDRN and GDOC for a compendium of PC biomarkers, 
but we did not find any datasets, emphasizing that the 
application of metabolomics for PC biomarker research 
is relatively new.  Furthermore, bulk of PC biomarkers 
studies using a metabolomics approach were published in 
years 2010 to 2016, underscoring the emerging nature of 
this field of research.  
Following literature search, biomarkers were 
stratified based on the type of matrix used for biomarker 
discovery (ex. tissue, saliva, cell lines, blood or urine).
We focused on  blood based metabolite markers for meta-
analysis  (Table 1 and Supplementary Table 1), while all 
non-blood based studies, such as tissue, urine, and saliva, 
were consolidated separately (Supplementary Table 2). 
All blood based metabolite markers that overlapped in 
two or more studies were deemed significant for further 
evaluation and were compiled along with the comparative 
groups and direction of regulation as reported (Table 1). 
Approximately 56 metabolite markers that were found to 
be significantly dysregulated in blood samples obtained 
from “at-diagnosis” PC patients as compared to normal 
controls, uniquely reported by one research group, are 
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Table 1: Compendium of blood based metabolite markers that overlapped between independently 
conducted case- control biomarkers studies of PC
Biomarker Comparison Groups Instrument Matrix Reference
1,5-anhydro-d-glucitol↓b PC (n = 200) vs NC (n = 200) LC–TOFMS, GC–TOFMS plasma [82]
PC (n = 43) vs NC (n = 42) GC/MS serum [65]
3-hydroxybutyrate ↓ PC (n = 17) vs NC (n = 23) 1H NMR Serum [38]
PC (n = 19) vs NC (n = 20)c H-NMR Blood/plasma [64]
Alanine ↓ PC (n = 19) vs NC (n = 20)c H-NMR Blood/plasma [64]
PC (n = 360) vs NC (n = 8372)c HPLC-ESI-MS plasma [63]
Asparaginea PC (n = 43) vs NC (n = 42) GC/MS Serum [65]
PC (n = 20) vs NC (n = 9) GC/MS Serum [66]
PC (n = 360) vs NC (n = 8372)c HPLC-ESI-MS plasma [63]
CA19-9 ↑ b PC (n = 84) vs NC (n = 99) tandem mass spectrometry Serum [83]
PC (n = 50) vs NC (n = 50)c ELISA serum [84]
Cholinea PC (n = 14) vs NC (n = 14) 1H NMR, TOCSY, HMQC or HSQC serum [85]
PC (n = 200) vs NC (n = 200) LC–TOFMS and  GC–TOFMS plasma [82]
Glutamatea PC (n = 19) vs NC (n = 20)c H-NMR Blood/plasma [64]
PC (n = 200) vs NC (n = 200) LC–TOFMS and 
 GC–TOFMS
plasma [82]
Glutamine ↓ PC (n = 5) vs NC (n = 2)c HILIC-LC/MS RP-LC/MS plasma [86]
PC (n = 19) vs NC (n = 20)c H-NMR Blood/plasma [64]
PC (n = 43) vs NC (n = 42) GC/MS Serum [65]
Histidine ↓ PC (n = 19) vs NC (n = 20)c H-NMR Blood/plasma [64]
PC (n = 43) vs NC (n = 42) GC/MS Serum [65]
PC (n = 360) vs NC (n = 8372)c HPLC-ESI-MS plasma [63]
Isoleucine ↑ PC (n = 17) vs NC (n = 23) 1H NMR Serum [38]
PC (n = 19) vs NC (n = 20)c H-NMR Blood/plasma [64]
Lactatea PC (n = 17) vs NC (n = 23) 1H NMR Serum [38]
PC (n = 19) vs NC (n = 20)c H-NMR Blood/plasma [64]
PC (n = 20) vs NC (n = 9) GC/MS serum [66]
Leucinea PC (n = 17) vs NC (n = 23) 1H NMR Serum [38]
PC (n = 360) vs NC (n = 8372)c HPLC-ESI-MS plasma [63]
Lysinea PC (n = 5) vs NC (n = 2)c HILIC-LC/MS plasma [86]
PC (n = 19) vs NC (n = 20)c H-NMR Blood/plasma [64]
PC (n = 43) vs NC (n = 42) GC/MS Serum [65]
PC (n = 360) vs NC (n = 8372)c HPLC-ESI-MS plasma [63]
LysoPC(18:2)a PC (n = 5) vs NC (n = 2)c RP-LC/MS plasma [86]
PC (n = 40) vs NC (n = 50) FI-FTICR-MS serum [87]
Methionine ↓ PC (n = 360) vs NC (n = 8372)c HPLC-ESI-MS plasma [63]
PC (n = 43) vs NC (n = 42) GC/MS Serum [65]
Phenylalaninea PC (n = 360) vs NC (n = 8372)c HPLC-ESI-MS plasma [63]
PC (n = 5) vs NC (n = 2)c RP-LC/MS plasma [86]
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listed in Supplementary Table 1.  In addition, studies 
that used high risk cohorts (such as benign pancreatic 
conditions and chronic pancreatitis) as a reference 
group for delineating PC biomarkers are detailed in 
Supplementary Table 1 showing some overlap with those 
listed in Table 1.
Experimental evaluation of blood based 
biomarkers of PC
We chose blood-based metabolites for meta-analysis 
since it is a non-invasive matrix enabling easy sample 
collection. Furthermore it is amenable to the development 
of an assay that can be translated into clinical use with 
relative ease and in a cost-effective manner as compared 
to a more invasive procedure like tissue biopsy.
Our study included plasma samples from four 
diagnostic groups including PC (N = 59), normal controls 
(N = 48), CRC (N = 66) and T2DM (N = 19) that were 
used for performance evaluation of literature curated 
biomarkers. PC and CRC groups had localized cancer 
at the time of sample collection and were not previously 
treated with cancer therapies. The underlying rationale 
for choosing the latter two cohorts (CRC and T2DM), 
was to evaluate biomarker specificity for PC. We used 
stable isotope labeling and multiple reaction monitoring 
(SID-MRM) based targeted mass spectrometry (MS), 
for measuring relative abundance for 18 metabolites (of 
the reported 21 listed in Table 1). Three metabolites, 
namely 1,5-anhydro-d-gluticol, CA19-9, and PC-594 
were not quantified in our panel, and hence were not used 
in subsequent analyses. Test of significance between the 
control and PC groups showed that, seventeen metabolites 
had a significant p-value after applying multiple testing 
correction. Next we computed relative ratios between 
the normal controls and PC to select ten metabolites 
that showed a relative fold change of greater than 1.8 or 
less than 0.7. This is an arbitrary cut-off and was used 
primarily because it has been used in several “omics” 
based biomarker studies [51]. Metabolite marker selection 
based on p-value and fold change helped delineate a ten 
metabolite panel (Table 2). Our analysis showed that 
eight of the ten metabolites were down-regulated in 
PC, including lactate, LysoPC (18:2), alanine, choline, 
threonine, asparagine, tyrosine, and lysine. Palmitate and 
3-hydroxybutyrate were upregulated in PC when compared 
to normal controls.  Group separation between PC and 
normal controls for each of the significant metabolites was 
visualized as box plots that were generated using in-house 
R scripts (Figure 1).  
Next we evaluated the efficiency of the ten-biomarker 
panel using biomarker analysis module of MetaboAnalyst 
v3.0 [52]. A random forest based multivariate ROC analysis 
using t-statistics for metabolite ranking resulted in a panel 
yielding an AUC of 0.992 (Figure 2) for PC, emphasizing 
high accuracy of this literature-curated classifier. 
Subsequently we used control cohorts to test biomarker 
panel specificity. Test of significance for all comparisons are 
detailed in Table 2.  ROC analysis using the same parameters 
for the ten metabolites yielded an AUC of 0.986 (Figure 3) 
for colorectal cancer vs NC, and an AUC of 0.957 (Figure 4) 
for T2DM vs NC.  Strikingly, test of significance for 
CRC vs NC (based on p-value and fold change cut-offs), 
yielded 8 of the 10 metabolites as being significant and the 
direction of regulation was also concordant as in NC vs PC 
(asparagine and threonine were non-significant).  These 
results suggest a high degree of correlation between the two 
cancer malignancies with respect to metabolic dysregulation 
(> 75%) evidenced through our metabolite panel. Not 
surprisingly, the ten-metabolite panel proved to be a poor 
classifier for CRC vs PC (AUC = 0.65) (Figure 5). 
We also compared T2DM cohort (N =  19) against 
normal controls, finding 3 metabolites (asparagine, lactate 
and palmitate) of the 10 to be significantly dysregulated 
between these two groups.  The ROC curve generated 
using the ten-metabolite panel discriminated T2DM 
Palmitic acid ↓ PC (n = 40) vs NC (n = 40) LC-MS/MS serum [57]
PC (n = 20) vs NC (n = 9) GC/MS serum [66]
PC-594 ↓b PC (n = 84) vs NC (n = 99) tandem mass spectrometry Serum [83]
PC (n = 40) vs NC (n = 50) FI-FTICR-MS serum [87]
Threonine ↓ PC (n = 360) vs NC (n = 8372)c HPLC-ESI-MS plasma [63]
PC (n = 43) vs NC (n = 42) GC/MS Serum [65]
Tyrosine ↓ PC (n = 360) vs NC (n = 8372)c HPLC-ESI-MS plasma [63]
PC (n = 43) vs NC (n = 42) GC/MS Serum [65]
Valine ↓ PC (n = 19) vs NC (n = 20)c H-NMR Blood/plasma [64]
PC (n = 43) vs NC (n = 42) GC/MS Serum [65]
PC (n = 360) vs NC (n = 8372)c HPLC-ESI-MS plasma [63]
aMetabolites that were found in multiple studies but were non-concordant.
bMetabolites that were found in multiple studies but were not included in our analysis.
cPC vs Chronic pancreatitis.
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patients from PC patients with high accuracy (AUC = 
0.997) (Figure 6). In order to assess if age or gender can 
significantly improve prediction of patient groups, the 
receiver operating characteristic (ROC) curves of the 
ten metabolite panel with age or gender are compared 
with the ROC curves of the panel only using three 
different statistical methods namely Delong, Bootstrap 
and Venkatraman tests [53–55]. P-values less than 0.05 
are considered statistically significant. Our results show 
that all the three tests have consistent results for the ROC 
curves comparisons, both age and sex did not help change 
the ROC curves significantly for NC vs PDAC, NC vs 
CRC and NC vs T2DM, only age helped to change the 
ROC curve and improve the AUC value significantly for 
PDAC vs CRC.
A multinomial logistic regression model with the 
10 blood (serum/plasma) analytes and patient’s age was 
used to generate a plasma 10 metabolite index (P10MI) 
in order to distinguish between PC, CRC, T2DM and 
normal control groups (Figure 7).  Higher calculated index 
Figure 1: Boxplots for the ten metabolite panel. Group separation based on normalized abundance of the ten dysregulated 
metabolites in PC as compared to NC. Solid line represents median value.
Table 2: Experimental validation of a ten metabolite PC biomarker panel curated from literature 
NC vs PC NC vs CRC NC vs T2DM T2DM vs PC CRC vs PC
Metabolite FDR Fold Change FDR Fold Change FDR Fold Change FDR Fold Change FDR Fold Change 
*Lactate 8.66e-15 0.33(↓) 5.25e-13 0.39(↓) 1.48e-07 2.19(↑) 1.22e-15 0.15 (↓) 0.52 0.84
*LysoPC(18:2) 1.45e-12 0.49(↓) 7.33e-16 0.46(↓) 0.55 1.05 6.80e-9 0.47 (↓) 0.94 1.06
Alanine 2.73e-16 0.56(↓) 3.67e-20 0.54(↓) 0.14 1.12 1.13e-12 0.49 (↓) 0.94 1.03
*Choline 0.01 0.68(↓) 0.0003 0.58(↓) 0.21 1.14 0.0019 0.59 (↓) 0.52 1.16
Threonine 1.15e-08 0.69 (↓) 6.40e-09 0.72 0.14 1.11 1.44e-7 0.62 (↓) 0.52 0.95
*Asparagine 7.58e-10 0.70(↓) 3.70e-06 0.79 2.59e-17 0.32(↓) 1.14e-12 2.16 (↑) 0.059 0.88
Tyrosine 1.07e-09 0.70(↓) 3.04e-13 0.66(↓) 0.81 1.01 2.38e-7 0.69 (↓) 0.52 1.05
*Lysine 1.49e-09 0.70(↓) 1.43e-10 0.70(↓) 0.04 1.15 1.032e-9 0.61 (↓) 0.94 1.00
Palmitate 2.47e-15 2.35(↑) 6.09e-12 3.60(↑) 0.007 2.47 (↑) 0.019 0.95 0.94 0.65(↓)
3-hydroxybutyrate 4.64e-13 6.91(↑) 9.29e-23 17.19(↑) 0.88 1.20 2.49e-7 5.77 (↑) 4.59e-4 0.40(↓)
Metabolites marked with an asterix are not concordant across reported studies.
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values are associated with a higher risk of PC diagnosis, 
with confidence transitioning from 90% to 100% at 12.5. 
Based on calculated P10MI in our dataset, a value ≥ 12.5 
represents a true PC case, with a 100% risk of being 
diagnosed with PC.  Notably, there was relatively low 
variability of the P10MI for both the NC and the T2DM 
groups, with low overlap, with the PC group (dots outside 
error bars). On the other hand, there was a significant 
overlap between the PC and CRC groups, suggesting a 
lack of specificity of this panel for PC alone. 
DISCUSSION
The PRoBE design for biomarker development 
described by Pepe et al. involves biomarker discovery, 
followed by rigorous evaluation of biomarker performance, 
and finally its impact on predicting clinical outcomes [56]. 
Despite an array of biomarker studies of PC, there is a 
paucity of predictive or prognostic biomarker panels of 
PC that have received regulatory approvals.  Moreover, PC 
has a relatively low prevalence (10/100,000 individuals in 
the USA), hence it is imperative that a biomarker panel of 
PC has a high specificity, thereby limiting false positives 
when screening a high risk population. Although there are 
a number of metabolomics-based PC biomarker studies, 
most have used (“at-diagnosis”) case-control designs 
that are subject to serious selection bias, limiting their 
general applicability to high risk populations [57, 58]. 
Developing a specific and sensitive panel of biomarkers 
offers a pragmatic approach towards increasing overall 
survival rates while identifying putative molecular targets 
for therapeutic development, and improving treatment 
strategies and clinical outcomes. Delineation of clinically 
useful biomarkers, however, requires implementation of 
well-designed studies for biomarker discovery followed 
by rigorous and blinded external validation for evaluating 
classification accuracy [59–62].
 Creating a compendium of existing biomarker data 
and performing meta-analyses represent the first steps 
in the development of clinical assays for PC diagnosis 
and prognosis. Herein, we performed an exhaustive 
literature search to find PC case-control studies reporting 
dysregulated metabolites associated with PC, primarily 
from three different sources: PubMed, EDRN and GDOC 
(Georgetown Database of Cancer), using different search 
keywords. We delineated 21 metabolites (that included 
amino acids, glycerophospholipids, fatty acids and small 
organic acids) that were reported by two or more research 
groups as being dysregulated in PC. Next, we used stable 
isotope dilution multiple-reaction monitoring mass 
spectrometry (SID- MRM-MS) for targeted quantitation 
of these 21 metabolite markers in plasma samples 
Figure 2: Receiver-operating characteristic (ROC) curve for PC (n = 59) vs NC (n = 48) using the ten metabolite panel 
yields AUC = 0.992.
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Figure 3: Receiver-operating characteristic (ROC) curve for CRC (n = 66) vs NC (n = 48) using the ten metabolite 
panel yields AUC = 0.986.
Figure 4: Receiver-operating characteristic (ROC) curve for T2DM (n = 19) vs NC (n = 48) using the ten metabolite 
panel yields AUC = 0.957.
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Figure 6: Receiver-operating characteristic (ROC) curve T2DM (n = 19) vs PC (n = 59) using the ten metabolite panel 
yields AUC = 0.997.
Figure 5: Receiver-operating characteristic (ROC) curve for CRC (n = 66) vs PC (n = 59) using the ten metabolite 
panel yields AUC = 0.653.
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obtained from patients that were diagnosed with PC and 
compared the profiles to normal controls with a similar 
median age and near uniform gender distribution. The PC 
patient samples (N = 59) were made available through 
the Indivumed repository at the MedStar-Georgetown 
University hospital while the normal controls (N = 48) 
were recruited at University of Rochester under approved 
IRB protocols. We also included plasma samples obtained 
from patients diagnosed with Type 2 diabetes (N = 19) or 
colorectal cancer (N = 66) as control cohorts to evaluate 
specificity of the biomarker panel. 
The ten metabolite biomarkers delineated in 
this study using literature curation were found to be 
significantly dysregulated in PC patients as compared to 
normal controls. However, five of the metabolites (Lyso 
PC18:2, lactate, choline, lysine and asparagine) were 
not concordant across reported studies (Tables 1 and 2). 
Three metabolites, alanine [63, 64], threonine [63, 65], 
and tyrosine [63, 65], were found to be concordant with 
results from our study as well as across reported literature. 
On the other hand, 3-hydroxybuyterate [38, 64] and 
palmitate [57, 66], were reported to be down-regulated 
in PC across reported studies; however these metabolites 
were significantly up-regulated in PC patient samples 
upon analysis in our laboratory, with fold change values 
of 6.9 and 2.3 fold, respectively. These findings therefore, 
would need further investigations and cross-validation. 
Additionally, conflicting results in published literature 
further emphasize the need for a centralized biomarker 
repository to facilitate cross-laboratory and cross-platform 
evaluation of classifiers. One of the limitations of the 
meta-analysis could stem from the fact that PC and CRC 
samples used in our study represented localized and early 
stage disease while the data from the surveyed literature 
search included all stages, potentially lending to analytical 
variability.
In this study we used, CRC (as a cancer disease 
control) and T2DM (as a non-cancer control) cohorts 
for testing biomarker specificity. Several metabolite 
markers (eight of ten) overlapped between pancreatic 
cancer and colorectal cancer including, LysoPC (18:2), 
alanine, choline, tyrosine, lysine, and 3-hydroxybutyrate 
suggesting a generic metabolic perturbation pattern that 
underscores a cancerous metabotype.  Furthermore, all of 
these metabolites have the same direction of regulation in 
the two cancer groups although their fold changes vary 
when compared to the normal controls.
 Although T2DM has been intricately linked to 
the onset of PC [48], the degree of overlap between the 
metabolic markers between the two disease was much less 
(around 10–15%). The T2DM cohort used in this study 
was much younger and obtained from an Asian population 
as compared to the NCs and the PC cases which were 
primarily Caucasian; this is a potential weakness of 
Figure 7: Boxplot depiction of the plasma 10 metabolite index (P10MI). Solid black horizontal line within the boxplots 
represents mean value.
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the study cohort although we performed statistical 
analysis to rule out bias in resultant AUCs for different 
comparative groups. Additionally, a review of literature 
reporting metabolite profiling of NC vs T2DM using 
diverse populations show partial overlap with the markers 
delineated in this study [67–70]. These results emphasize 
the need to include related disease control cohorts that 
share commonalities with oncogenic progression of 
pancreatic cancer; these would warrant inclusion of other 
cancer cohorts as cancer disease controls but also those 
deemed to be high risk cohorts of PC such as patients 
diagnosed with chronic pancreatitis or with non-malignant 
precursor lesions of the pancreas.
Several signaling pathways that are altered during 
carcinogenesis are known to impact metabolic processes 
[71]. Given that several genetic mutations and signaling 
pathways overlap between different malignancies, it 
is reasonable to assume that this would result in shared 
metabolic dysregulations. Therefore, inclusion of cancer 
disease control and high-risk cohorts for PC biomarker 
studies is critical for eliminating non-specific metabolites 
that would otherwise diminish the clinical utility of the 
biomarker panel for PC diagnosis.
While we used CRC and T2DM as control for 
specificity, some papers from our literature survey 
included chronic pancreatitis (CP) or benign pancreatic 
conditions in their study.  Overlapping biomarkers 
between chronic pancreatitis and our literature derived 
panel included lactate, lysine, histidine, glutamine, 
glutamate, and alanine, which were found elevated in 
CP vs NC [64].  Additionally, a comparison of CP and 
PC diagnostic groups yielded 3-hydroxybutyrate, lactate, 
valine, tyrosine, phenylalanine, lysine, isoleucine, 
histidine, glutamine, glutamate, and alanine as being up-
regulated in chronic pancreatitis [64].  Comparison of 
PC and  benign pancreatitis cases showed upregulation 
of  3-hydroxybutyrate and phenylalanine in PC, while 
lysine, asparagine, and threonine were down-regulated 
[44]. Threonine emerged as a specific marker for PC, 
although we could not include 1,5-anhydro-d-gluticol, 
CA19-9, and PC-594 in this analysis. The AUC for NC vs 
PC for threonine was 0.84 thus emphasizing the need for 
continued efforts to delineate a biomarker panel with high 
specificity for PC (Figure 8).
Discovery and validation of novel and robust 
biomarkers is integral to advance personalized medicine 
initiative. However, there is huge gap between reported 
cancer biomarker studies and their translation into 
potential clinical use [72].  Advancing the translation 
of biomarkers from a scientific discovery to regulatory 
approvals for clinical implementation would require a 
concerted effort [73]. This includes a) improvements in 
guidelines for designing biomarker development studies 
for evaluation of biomarker specificity and sensitivity; b) 
availability of high quality bio-specimens (with clinical 
annotations) by controlling sample collection and storage 
procedures; c) application of scientific, analytical and 
statistical rigor to the study design; d) standardization of 
data reporting guidelines for biomarker discovery studies 
thus enabling meta-analyses; e) data sharing to facilitate 
cross-platform an inter-laboratory reproducibility studies; 
f) external biomarker validation studies performed with 
GLP compliance [74]. Collectively, these measures would 
maximize the development of robust biomarker panels that 
would be ready for clinical testing; in addition this would 
also augment testing a combination of “omics” markers 
that would form better classifiers. It would also lead to 
mechanistic studies aimed at discerning how pathway 
perturbations lead to the observed disease phenotype. 
Understanding of biochemical alterations that underscore 
cancer progression, reflected as biomarkers, allows for a 
more practical way of identifying molecular targets that 
can be used for customized therapeutic development. 
MATERIALS AND METHODS
Databases used
A large number of studies related to pancreatic 
cancer biomarkers have been indexed on multiple 
platforms.  In order to identify relevant metabolomics 
studies, we focused our literature searches to PubMed, 
as well as the biomarker data repositories EDRN (Early 
Detection Research Network) and G-DOC (Georgetown 
Database of Cancer).   PubMed is a database that contains 
abstract and full-text citations for biomedical literature 
from MEDLINE, life science journals, and online books, 
and is maintained by United States National Library of 
Medicine (NLM) at the National Institute of Health 
(NIH).  EDRN, led by the National Cancer Institute (NCI), 
is a collaboration focused on the discovery and clinical 
application of cancer biomarkers.  G-DOC is a platform 
that combines data integration and integrative knowledge 
discovery for oncological and translational research 
communities. In our approach (Figure 9), “pancreatic 
cancer” is searched in PubMed, which generates over 
80,000 results.  To narrow down the search results, 
different permutations of keywords pertaining to PC 
biomarkers were searched.  As of December 2016 the 
eight keywords that returned results for metabolomics 
based biomarker studies of PC that have been  cited in 
this study are listed, along with number of search results 
generated (‘Keywords Used’, Figure 9).  On the other 
hand, “pancreatic ductal adenocarcinoma” and “pancreatic 
cancer” were used as search terms in the two previously 
discussed cancer biomarker repositories, G-DOC and 
EDRN.  
Not all of the eight keywords used for searching 
PubMed generate results that are relevant for this 
study and hence were parsed. For instance, some 
studies focus on the structural biology of a metabolite 
while other studies had a bioinformatics focus.  Each 
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PubMed paper was manually curated for parsing 
information and determining suitability for the 
proposed meta-analysis.  
Manual curation procedures and criteria for 
including metabolites
The second screening step involves mining 
literature for the name of the metabolite and verifying 
contextual data for which it was discovered in previous 
studies.  Each metabolite recorded in the final literature 
search must be strictly curated for the following criteria. 
Firstly, only studies with human-based matrices (urine, 
cell lines, tissue, plasma, serum) are allowed; no animal 
studies or animal to human comparative studies were 
included.  Metabolites derived from the comparing 
of pancreatic cancer patients vs. normal patients, or 
controls were segregated from other comparisons.  The 
sample size, technology used in biomarker discovery (i.e. 
mass spectrometry, NMR, etc.) and most importantly, 
and the direction of regulation of the biomarker were 
documented.  We observed that not all studies found 
had information pertaining to all these categories 
emphasizing the need to standardize reporting guidelines 
for biomarker studies.  An additional author-specific 
search was accomplished by mining the bibliography of 
different studies for additional relevant papers that may 
not have appeared in the initial PubMed search.  Review 
articles found on PubMed were also cross-referenced, 
in order to verify that metabolite data were recorded 
correctly.  
Study participant and samples
A total of 192 plasma samples were analyzed with 
four diagnostic groups: PC, CRC, T2DM, and normal 
controls. PC (n = 59) and CRC (n = 66) samples were 
made available through the Indivumed repository 
at the MedStar-Georgetown University hospital 
protocols. PC and CRC patients were candidates for 
curative surgery and hence represented previously 
untreated early stages of cancer. Normal controls 
(n = 48) were recruited as a part of the Rochester aging 
study (RAS) under approved IRB protocols [75]. Plasma 
samples from patients with a diagnosis of T2DM (n = 19) 
(without any co-morbidity) were collected under approved 
IRB protocols in Qatar University [76, 77]. Clinical and 
demographic characteristics of the cohort as age, sex, 
ethnicity were recorded (Table 3). All samples were 
collected under 12 hour fasting conditions using stringent 
procedures for collection and storage thus minimizing 
confounding by pre-analytical variables on downstream 
MS analyses.  Other factors and coexisting conditions 
such as BMI, jaundice, diabetes and smoking, alcohol 
traits for each subject were also annotated.
Targeted liquid chromatography-mass 
spectrometry
Targeted analyses were performed using plasma 
samples  on  a Acquity UPLC (Waters Corporation, 
USA) online with a triple quadrupole MS  (Xevo 
TQ-S Waters Corporation, USA) operating in the 
Figure 8: Receiver-operating characteristic (ROC) curve and for PC (n = 59) vs NC (n = 48) metabolite threonine 
yields AUC = 0.843. 
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Table 3: Demographic details of the study participants
PC (n = 59) CRC (n = 66) T2DM (n = 19) Normal (n = 48)
Median Age 74.2 63.45 55 79
Ethnicity
Caucasian 33 46 0 47
African American 13 11 3 1
Asian 7 8 16 0
Hispanic 2 0 0 0
Other 4 1 0 0
Gender
Male 28 31 17 25
Female 31 35 2 23
Type II Diabetes 22 6 19 5
Mean BMI 25.072 25.829 29.525 26.175
Alcohol 20 33 0 35
Smoking 29 37 12 4
Jaundice 27 0 0 0
Figure 9: Schema for curating metabolites mined from literature search and meta- analyses. 
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MRM mode.  Different classes of metabolites such as 
amino acids, biogenic amines, glycerophospholipids, 
acylcarnitines, sphingolipids and sugars were analyzed 
using AbsoluteIDQ® p180 kit (Biocrates Life Sciences 
AG, Innsbruck, Austria) as detailed  by the manufacturer 
as described previously [75].  
We also performed targeted mass spectrometry 
based quantification for 3-hydroxybutyrate, choline, 
lactate, palmitate, using a separate extraction. 15 ul of 
serum/plasma were mixed with 95 ul methanol containing 
500 nM each of 17 isotopically labeled internal standards 
(Cambridge Isotope Labs product number MSK-A2-1.2) 
and vortexed for 20 seconds.  After adding 190 ul 
dichloromethane, samples were again vortexed for 
20 seconds. Finally, 60 ul water were added and 
the samples were vortexed for 10 min. at 4C, then 
centrifuged at 8,000 × g for 10 min. at 4°C. The two 
solvent layers were collected separately and dried under 
vacuum, then stored at −80C. The top (polar) layer was 
resuspended in 100 ul water and 1 ul was injected for 
LC/MS analysis as described [78]. The bottom (lipid) 
layer was resuspended in 50 ul 65:30:5 acetonitrile/
isopropanol/water (v/v/v) and 5 ul was injected for LC/
MS analysis as described [79].
Statistical and bioinformatics analysis
Statistical analysis of the MS data were performed 
using MetaboAnalyst 3.0 [80]. Initially we used the 
statistical analysis module of MetaboAnalyst 3.0. Data 
were log transformed before performing t-statistics to 
delineate significant metabolites using fold change and test 
of significance as thresholds.  Metabolites with an adjusted 
p-value of less than 0.05 and a fold change either less than 
or equal to 0.7 or greater than 1.8 were deemed significant 
for constructing a binary classifier using ROC analysis 
module of MetaboAnalyst v 3.0. Box plots were plotted 
using in-house R scripts. Plasma index metabolite index 
was calculated using a multinomial logistic regression 
model in R as described previously [81].
Abbreviations
PC (Pancreatic Cancer), NC (Normal Control), 
CRC (Colorectal Cancer), T2DM (Type II Diabetes), CP 
(Chronic Pancreatitis).
Author contributions
AKC, KU, HJF, MSF and MM conceived the 
study. NR provided T2DM samples for the study. 
SSM performed MS experiments. KYM and XZ 
performed statistical analysis. HJ and YF performed 
literature search and curated biomarker panel for PC 
and consolidated results. All authors contributed to the 
writing of the paper.
ACKNOWLEDGMENTS
 The authors would like to thank Dr. Elizaveta 
Frienkman for help with targeted MS analysis of plasma 
samples. The authors would also like to thank Ms. Nan Hu 
and Mr. Joe Lewis with the literature mining for curated 
biomarkers.
CONFLICTS OF INTEREST
The authors declare no competing conflicts of 
interest.
FUNDING
This work was supported by ACS IRG-92-152-17 
pilot award number AWD4470404 to KU and AKC. The 
authors would like to acknowledge the Metabolomics 
Shared Resource in Georgetown University (Washington 
DC, USA) partially supported by NIH/NCI/CCSG grant 
P30-CA051008.
REFERENCES
 1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. 
CA Cancer J Clin. 2017; 67:7–30. https://doi.org/10.3322/
caac.21387.
 2. Krechler T, Horejs J, Ulrych J, Zeman M, Macasek J, 
Duskova J, Zak A. Current status of pancreatic cancer 
diagnosis. Cas Lek Cesk. 2011; 150:587–93.
 3. Matthaios D, Zarogoulidis P, Balgouranidou I, Chatzaki E, 
Kakolyris S. Molecular pathogenesis of pancreatic cancer 
and clinical perspectives. Oncology. 2011; 81:259–72. 
https://doi.org/10.1159/000334449.
 4. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, 
Fleshman JM, Matrisian LM. Projecting Cancer Incidence 
and Deaths to 2030: The Unexpected Burden of Thyroid, 
Liver, and Pancreas Cancers in the United States. Cancer 
Research. 2014; 74:2913–21. 
 5. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. 
Lancet. 2004; 363:1049–57. https://doi.org/10.1016/S0140-
673615841-8S.
 6. McWilliams RR, Maisonneuve P, Bamlet WR, Petersen 
GM, Li D, Risch HA, Yu H, Fontham ET, Luckett B, 
Bosetti C, Negri E, La Vecchia C, Talamini R, et al. Risk 
Factors for Early-Onset and Very-Early-Onset Pancreatic 
Adenocarcinoma: A Pancreatic Cancer Case-Control 
Consortium (PanC4) Analysis. Pancreas. 2016; 45:311–6. 
https://doi.org/10.1097/MPA.0000000000000392.
 7. Casari I, Falasca M. Diet and Pancreatic Cancer Prevention. 
Cancers (Basel). 2015; 7:2309–17. https://doi.org/10.3390/
cancers7040892.
 8. Taunk P, Hecht E, Stolzenberg-Solomon R. Are meat and 
heme iron intake associated with pancreatic cancer? Results 
Oncotarget68912www.impactjournals.com/oncotarget
from the NIH-AARP Diet and Health Cohort. Int J Cancer. 
2016; 138:2172–89. https://doi.org/10.1002/ijc.29964.
 9. Kim VM, Ahuja N. Early detection of pancreatic cancer. 
Chin J Cancer Res. 2015; 27:321–31. https://doi.
org/10.3978/j.issn.1000-9604.2015.07.03.
10. Majumder S, Chari ST, Ahlquist DA. Molecular detection 
of pancreatic neoplasia: Current status and future promise. 
World J Gastroenterol. 2015; 21:11387–95. https://doi.
org/10.3748/wjg.v21.i40.11387.
11. Honda K, Kobayashi M, Okusaka T, Rinaudo JA, Huang Y, 
Marsh T, Sanada M, Sasajima Y, Nakamori S, Shimahara 
M, Ueno T, Tsuchida A, Sata N, et al. Plasma biomarker 
for detection of early stage pancreatic cancer and risk 
factors for pancreatic malignancy using antibodies for 
apolipoprotein-AII isoforms. Sci Rep. 2015; 5:15921. 
https://doi.org/10.1038/srep15921.
12. Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, 
Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra 
A, Tempero MA, Brand R, et al. Sequential Validation of 
Blood-Based Protein Biomarker Candidates for Early-Stage 
Pancreatic Cancer. J Natl Cancer Inst. 2017; 109. https://
doi.org/10.1093/jnci/djw266.
13. Swords DS, Firpo MA, Scaife CL, Mulvihill SJ. Biomarkers 
in pancreatic adenocarcinoma: current perspectives. Onco 
Targets Ther. 2016; 9:7459–67. https://doi.org/10.2147/
OTT.S100510.
14. Harsha HC, Kandasamy K, Ranganathan P, Rani S, 
Ramabadran S, Gollapudi S, Balakrishnan L, Dwivedi 
SB, Telikicherla D, Selvan LD, Goel R, Mathivanan S, 
Marimuthu A, et al. A compendium of potential biomarkers 
of pancreatic cancer. PLoS Med. 2009; 6:e1000046. https://
doi.org/10.1371/journal.pmed.1000046.
15. Asuthkar S, Rao JS, Gondi CS. Drugs in preclinical and 
early-stage clinical development for pancreatic cancer. 
Expert Opin Investig Drugs. 2012; 21:143–52. https://doi.
org/10.1517/13543784.2012.651124.
16. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, 
Zhuang R, Ning G, Zhang C, Yuan Y, Li Z, Zen K, et al. 
Serum MicroRNA Expression Profile as a Biomarker 
in the Diagnosis and Prognosis of Pancreatic Cancer. 
Clin Chem. 2012; 58:610–8. https://doi.org/10.1373/
clinchem.2011.172767.
17. Topilow AA, Davis JM, Vernick JJ, Tang D, Corbett S, 
Veltman T, Wagner SJ, Gilvarg C. Confirmation of a 
potential biomarker for early-stage pancreatic cancer. 
Cancer Biomark. 2011; 10:27–33. https://doi.org/10.3233/
CBM-2012-0225.
18. Kwon RS, Simeone DM. The use of protein-based 
biomarkers for the diagnosis of cystic tumors of the 
pancreas. Int J Proteomics. 2011; 2011:413646. https://doi.
org/10.1155/2011/413646.
19. Corcos O, Couvelard A, Dargere D, Sauvanet A, Hammel 
P, Paradis V, Levy P, Ruszniewski P, Bedossa P. Proteomic 
Assessment of Markers for Malignancy in the Mucus of 
Intraductal Papillary Mucinous Neoplasms of the Pancreas. 
Pancreas. 2012; 41:169–74. https://doi.org/10.1097/
MPA.0b013e3182289356.
20. Adamczyk B, Tharmalingam T, Rudd PM. Glycans as cancer 
biomarkers. Biochim Biophys Acta. 2012; 1820:1347–53. 
https://doi.org/10.1016/j.bbagen.2011.12.001.
21. Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, 
Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA. 
MicroRNA molecular profiles associated with diagnosis, 
clinicopathologic criteria, and overall survival in patients 
with resectable pancreatic ductal adenocarcinoma. Clin 
Cancer Res. 2012; 18:534–45. https://doi.org/10.1158/1078-
0432.CCR-11-0679.
22. Nolen BM, Brand RE, Prosser D, Velikokhatnaya L, Allen PJ, 
Zeh HJ, Grizzle WE, Lomakin A, Lokshin AE. Prediagnostic 
serum biomarkers as early detection tools for pancreatic 
cancer in a large prospective cohort study. PLoS One. 2014; 
9:e94928. https://doi.org/10.1371/journal.pone.0094928.
23. Tanday S. Biomarkers in blood could help to detect 
pancreatic cancer. Lancet Oncol. 2014; 15:e108. 
24. Floyd E, McShane TM. Development and use of biomarkers 
in oncology drug development. Toxicol Pathol. 2004; 
32:106–15. 
25. Jiang Y, Liu M, Li Z, Jiang Y. Discovery of novel candidate 
oncogenes in pancreatic carcinoma using high-throughput 
microarrays. Hepatogastroenterology. 2013; 60:1825–32.
26. Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, 
Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz 
M, Hollander NH, Andersen KK, Johansen JS. MicroRNA 
biomarkers in whole blood for detection of pancreatic 
cancer. JAMA. 2014; 311:392–404. https://doi.org/10.1001/
jama.2013.284664.
27. Khan S, Ansarullah, Kumar D, Jaggi M, Chauhan SC. 
Targeting microRNAs in pancreatic cancer: microplayers 
in the big game. Cancer Res. 2013; 73:6541–7. https://doi.
org/10.1158/0008-5472.CAN-13-1288.
28. Shaw VE, Lane B, Jenkinson C, Cox T, Greenhalf W, Halloran 
CM, Tang J, Sutton R, Neoptolemos JP, Costello E. Serum 
cytokine biomarker panels for discriminating pancreatic cancer 
from benign pancreatic disease. Mol Cancer. 2014; 13:114. 
https://doi.org/10.1186/1476-4598-13-114.
29. Thomas JK, Kim MS, Balakrishnan L, Nanjappa V, Raju R, 
Marimuthu A, Radhakrishnan A, Muthusamy B, Khan AA, 
Sakamuri S, Tankala SG, Singal M, Nair B, et al. Pancreatic 
Cancer Database: An integrative resource for pancreatic 
cancer. Cancer Biol Ther. 2014; 15:963–7. https://doi.
org/10.4161/cbt.2918.
30. Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli 
MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz 
HI. Alliance for Clinical Trials In O. Prognostic and 
predictive blood-based biomarkers in patients with 
advanced pancreatic cancer: results from CALGB80303 
(Alliance). Clin Cancer Res. 2013; 19:6957–66. https://doi.
org/10.1158/1078-0432.CCR-13-0926.
31. Costello E, Greenhalf W, Neoptolemos JP. New biomarkers 
and targets in pancreatic cancer and their application to 
treatment. Nat Rev Gastroenterol Hepatol. 2012; 9:435–44.
Oncotarget68913www.impactjournals.com/oncotarget
32. Le N, Sund M, Vinci A, and GEMS collaborating group 
of Pancreas 2000. Prognostic and predictive markers in 
pancreatic adenocarcinoma. Dig Liver Dis. 2016; 48:223–30. 
https://doi.org/10.1016/j.dld.2015.11.001.
33. Herreros-Villanueva M, Bujanda L. Non-invasive 
biomarkers in pancreatic cancer diagnosis: what we need 
versus what we have. Ann Transl Med. 2016; 4:134. https://
doi.org/10.21037/atm.2016.03.44.
34. Zhang Q, Chen S, Zeng L, Chen Y, Lian G, Qian C, Li J, 
Xie R, Huang KH. New developments in the early diagnosis 
of pancreatic cancer. Expert Rev Gastroenterol Hepatol. 
2017; 11:149–56. https://doi.org/10.1080/17474124.2017.
1271323.
35. Koen N, Du Preez I, Loots du T. Metabolomics and 
Personalized Medicine. Adv Protein Chem Struct Biol. 2016; 
102:53–78. https://doi.org/10.1016/bs.apcsb.2015.09.003.
36. Li S, Todor A, Luo R. Blood transcriptomics and 
metabolomics for personalized medicine. Comput Struct 
Biotechnol J. 2016; 14:1–7. https://doi.org/10.1016/j.
csbj.2015.10.005.
37. Armitage EG, Ciborowski M. Applications of Metabolomics 
in Cancer Studies. Adv Exp Med Biol. 2017; 965:209–34. 
https://doi.org 10.1007/978-3-319-47656-8_9.
38. OuYang D, Xu J, Huang H, Chen Z. Metabolomic profiling 
of serum from human pancreatic cancer patients using 1H 
NMR spectroscopy and principal component analysis. 
Appl Biochem Biotechnol. 2011; 165:148–54. https://doi.
org/10.1007/s12010-011-9240-0.
39. Stambuk S, Sundov D, Kuret S, Beljan R, Andelinovic 
S. Future perspectives of personalized oncology. Coll 
Antropol. 2010; 34:763–9.
40. Lowery MA, O'Reilly EM. Pancreatic cancer: the role of 
molecular markers in diagnosis and management. Clin Adv 
Hematol Oncol. 2011; 9:900–8. 
41. Franssen B, Chan C. Pancreatic Cancer: The surgeons point 
of view. Rev Gastroenterol Mex. 2011; 76:353–61. https://
doi.org/03750906764011.
42. Kaur P, Sheikh K, Kirilyuk A, Kirilyuk K, Singh R, Ressom 
HW, Cheema AK. Metabolomic profiling for biomarker 
discovery in pancreatic cancer. Int J Mass Spectrom. 2012; 
310:44–51.
43. Napoli C, Sperandio N, Lawlor RT, Scarpa A, Molinari 
H, Assfalg M. Urine metabolic signature of pancreatic 
ductal adenocarcinoma by h nuclear magnetic resonance: 
identification, mapping, and evolution. J Proteome Res. 
2012; 11:1274–83. https://doi.org/10.1021/pr200960u.
44. Bathe OF, Shaykhutdinov R, Kopciuk K, Weljie 
AM, McKay A, Sutherland FR, Dixon E, Dunse N, 
Sotiropoulos D, Vogel HJ. Feasibility of identifying 
pancreatic cancer based on serum metabolomics. Cancer 
Epidemiol Biomarkers Prev. 2011; 20:140–7. https://doi.
org/10.1158/1055-9965.EPI-10-0712.
45. Zhang H, Wang Y, Gu X, Zhou J, Yan C. Metabolomic 
profiling of human plasma in pancreatic cancer using 
pressurized capillary electrochromatography. Electrophoresis. 
2011; 32:340–7. https://doi.org/10.1002/elps.201000431.
46. Halbrook CJ, Lyssiotis CA. Employing Metabolism to 
Improve the Diagnosis and Treatment of Pancreatic Cancer. 
Cancer Cell. 2017; 31:5–19. https://doi.org/10.1016/j.
ccell.2016.12.006.
47. Hardie RA, van Dam E, Cowley M, Han TL, Balaban S, 
Pajic M, Pinese M, Iconomou M, Shearer RF, McKenna 
J, Miller D, Waddell N, Pearson JV, et al. Mitochondrial 
mutations and metabolic adaptation in pancreatic cancer. 
Cancer Metab. 2017; 5:2. https://doi.org/10.1186/s40170-
017-0164-1.
48. Wang F, Herrington M, Larsson J, Permert J. The 
relationship between diabetes and pancreatic cancer. 
Molecular Cancer. 2003; 2:4-. https://doi.org/10.1186/1476-
4598-2-4.
49. Gomez-Rubio P, Rosato V, Marquez M, Bosetti C, Molina-
Montes E, Rava M, Pinero J, Michalski CW, Farre A, 
Molero X, Lohr M, Ilzarbe L, Perea J, et al. A systems 
approach identifies time-dependent associations of 
multimorbidities with pancreatic cancer risk. Ann Oncol. 
2017; 28:1618–24. https://doi.org/10.1093/annonc/mdx167.
50. Chechlinska M, Kowalewska M, Nowak R. Systemic 
inflammation as a confounding factor in cancer biomarker 
discovery and validation. Nat Rev Cancer. 2010; 10:2–3.
51. McCarthy DJ, Smyth GK. Testing significance relative to 
a fold-change threshold is a TREAT. Bioinformatics. 2009; 
25:765–71. https://doi.org/10.1093/bioinformatics/btp053.
52. Xia J, Psychogios N, Young N, Wishart DS. MetaboAnalyst: 
a web server for metabolomic data analysis and 
interpretation. Nucleic Acids Res. 2009; 37:W652–60. 
https://doi.org/10.1093/nar/gkp356.
53. Venkatraman ES, Begg CB. A Distribution-Free Procedure 
for Comparing Receiver Operating Characteristic Curves 
from a Paired Experiment. Biometrika. 1996; 83:835–48.
54. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing 
the Areas under Two or More Correlated Receiver 
Operating Characteristic Curves: A Nonparametric 
Approach. Biometrics. 1988; 44:837–45. https://doi.
org/10.2307/2531595.
55. Venkatraman ES. A permutation test to compare receiver 
operating characteristic curves. Biometrics. 2000; 56:1134–8.
56. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. 
Pivotal evaluation of the accuracy of a biomarker used 
for classification or prediction: standards for study 
design. J Natl Cancer Inst. 2008; 100:1432–8. https://doi.
org/10.1093/jnci/djn326.
57. Di Gangi IM, Mazza T, Fontana A, Copetti M, Fusilli C, 
Ippolito A, Mattivi F, Latiano A, Andriulli A, Vrhovsek U, 
Pazienza V. Metabolomic profile in pancreatic cancer 
patients: a consensus-based approach to identify highly 
discriminating metabolites. Oncotarget. 2016; 7:5815–29. 
https://doi.org/10.18632/oncotarget.6808.
58. Fujiwara Y, Kobayashi T, Chayahara N, Imamura Y, 
Toyoda M, Kiyota N, Mukohara T, Nishiumi S, Azuma T, 
Oncotarget68914www.impactjournals.com/oncotarget
Yoshida M, Minami H. Metabolomics evaluation of serum 
markers for cachexia and their intra-day variation in 
patients with advanced pancreatic cancer. PLoS One. 2014; 
9:e113259. https://doi.org/10.1371/journal.pone.0113259.
59. Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu 
S, Mandruzzato S, Lee HM, Seliger B, Freedman RS, 
Taylor PR, Hu N, Zanovello P, et al. Common cancer 
biomarkers. Cancer Res. 2006; 66:2953–61. https://doi.
org/10.1158/0008-5472.CAN-05-3433.
60. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell 
metabolism. Nat Rev Cancer. 2011; 11:85–95. https://doi.
org/10.1038/nrc2981.
61. Seyfried TN, Shelton LM. Cancer as a metabolic disease. 
Nutr Metab (Lond). 2010; 7:7. https://doi.org/10.1186/1743-
7075-7-7.
62. Wu W, Zhao S. Metabolic changes in cancer: beyond the 
Warburg effect. Acta Biochim Biophys Sin (Shanghai). 
2013; 45:18–26. https://doi.org/10.1093/abbs/gms104.
63. Fukutake N, Ueno M, Hiraoka N, Shimada K, Shiraishi K, 
Saruki N, Ito T, Yamakado M, Ono N, Imaizumi A, Kikuchi 
S, Yamamoto H, Katayama K. A Novel Multivariate Index 
for Pancreatic Cancer Detection Based On the Plasma Free 
Amino Acid Profile. PLoS One. 2015; 10:e0132223. https://
doi.org/10.1371/journal.pone.0132223.
64. Zhang L, Jin H, Guo X, Yang Z, Zhao L, Tang S, Mo P, Wu 
K, Nie Y, Pan Y, Fan D. Distinguishing pancreatic cancer 
from chronic pancreatitis and healthy individuals by H 
nuclear magnetic resonance-based metabonomic profiles. 
Clin Biochem. 2012; 45:1064–9. https://doi.org/10.1016/j.
clinbiochem.2012.05.012.
65. Kobayashi T, Nishiumi S, Ikeda A, Yoshie T, Sakai A, 
Matsubara A, Izumi Y, Tsumura H, Tsuda M, Nishisaki H, 
Hayashi N, Kawano S, Fujiwara Y, et al. A novel serum 
metabolomics-based diagnostic approach to pancreatic 
cancer. Cancer Epidemiol Biomarkers Prev. 2013; 22:571–
9. https://doi.org/10.1158/1055-9965.EPI-12-1033.
66. Nishiumi S, Shinohara M, Ikeda A, Yoshie T, Hatano N, 
Kakuyama S, Mizuno S, Sanuki T, Kutsumi H, Fukusaki 
E, Azuma T, Takenawa T, Yoshida M. Serum metabolomics 
as a novel diagnostic approach for pancreatic cancer. 
Metabolomics. 2010; 6:518–28. https://doi.org/10.1007/
s11306-010-0224-9.
67. Peddinti G, Cobb J, Yengo L, Froguel P, Kravic J, Balkau 
B, Tuomi T, Aittokallio T, Groop L. Early metabolic 
markers identify potential targets for the prevention of type 
2 diabetes. Diabetologia. 2017; 60:1740–50. https://doi.
org/10.1007/s00125-017-4325-0.
68. Carter TC, Rein D, Padberg I, Peter E, Rennefahrt U, David 
DE, McManus V, Stefanski E, Martin S, Schatz P, Schrodi 
SJ. Validation of a metabolite panel for early diagnosis of 
type 2 diabetes. Metabolism. 2016; 65:1399–408. https://
doi.org/10.1016/j.metabol.2016.06.007.
69. Villarreal-Perez JZ, Villarreal-Martinez JZ, Lavalle-
Gonzalez FJ, Torres-Sepulveda Mdel R, Ruiz-Herrera C, 
Cerda-Flores RM, Castillo-Garcia ER, Rodriguez-Sanchez 
IP, Martinez de Villarreal LE. Plasma and urine metabolic 
profiles are reflective of altered beta-oxidation in non-
diabetic obese subjects and patients with type 2 diabetes 
mellitus. Diabetol Metab Syndr. 2014; 6:129. https://doi.
org/10.1186/1758-5996-6-129.
70. Kim M, Kim M, Han JY, Lee SH, Jee SH, Lee JH. The 
metabolites in peripheral blood mononuclear cells showed 
greater differences between patients with impaired fasting 
glucose or type 2 diabetes and healthy controls than those 
in plasma. Diab Vasc Dis Res. 2017; 14:130–8. https://doi.
org/10.1177/1479164116678157.
71. DeBerardinis RJ, Chandel NS. Fundamentals of cancer 
metabolism. Sci Adv. 2016; 2:e1600200. https://doi.
org/10.1126/sciadv.1600200.
72. Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer 
biomarker discovery and validation. Transl Cancer Res. 
2015; 4:256–69. https://doi.org/10.3978/j.issn.2218-
676X.2015.06.04.
73. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer 
biomarker profiling. Eur Urol. 2007; 52:1601–9. https://doi.
org/10.1016/j.eururo.2007.09.036.
74. Marton MJ, Weiner R. Practical Guidance for Implementing 
Predictive Biomarkers into Early Phase Clinical Studies. 
BioMed Research International. 2013; 2013:891391. https://
doi.org/10.1155/2013/891391.
75. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre 
TR, MacArthur LH, Hall WJ, Fisher SG, Peterson DR, 
Haley JM, Nazar MD, Rich SA, Berlau DJ, et al. Plasma 
phospholipids identify antecedent memory impairment 
in older adults. Nat Med. 2014; 20:415–8. https://doi.
org/10.1038/nm.3466.
76. Kaur P, Rizk N, Ibrahim S, Luo Y, Younes N, Perry B, 
Dennis K, Zirie M, Luta G, Cheema AK. Quantitative 
metabolomic and lipidomic profiling reveals aberrant amino 
acid metabolism in type 2 diabetes. Mol Biosyst. 2013; 
9:307–17.https://doi.org/10.1039/C2MB25384D.
77. Kaur P, Rizk NM, Ibrahim S, Younes N, Uppal A, Dennis 
K, Karve T, Blakeslee K, Kwagyan J, Zirie M, Ressom HW, 
Cheema AK. iTRAQ-based quantitative protein expression 
profiling and MRM verification of markers in type 2 
diabetes. J Proteome Res. 2012; 11:5527–39. https://doi.
org/10.1021/pr300798z.
78. Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Remaileh 
M, Sabatini DM. An Essential Role of the Mitochondrial 
Electron Transport Chain in Cell Proliferation Is to Enable 
Aspartate Synthesis. Cell. 2015; 162:540–51. https://doi.
org/10.1016/j.cell.2015.07.016.
79. Smulan LJ, Ding W, Freinkman E, Gujja S, Edwards YJ, 
Walker AK. Cholesterol-Independent SREBP-1 Maturation 
Is Linked to ARF1 Inactivation. Cell Reports. 2016; 16:9–
18. https://doi.org/10.1016/j.celrep.2016.05.086.
80. Xia J, Wishart DS. Using MetaboAnalyst 3.0 for 
Comprehensive Metabolomics Data Analysis. Curr 
Oncotarget68915www.impactjournals.com/oncotarget
Protoc Bioinformatics. 2016; 55:1401–091. https://doi.
org/10.1002/cpbi.11.
81. Fiandaca MS, Zhong X, Cheema AK, Orquiza MH, 
Chidambaram S, Tan MT, Gresenz CR, FitzGerald KT, 
Nalls MA, Singleton AB, Mapstone M, Federoff HJ. 
Plasma 24-metabolite Panel Predicts Preclinical Transition 
to Clinical Stages of Alzheimer's Disease. Front Neurol. 
2015; 6:237. https://doi.org/10.3389/fneur.2015.00237.
82. Xie G, Lu L, Qiu Y, Ni Q, Zhang W, Gao YT, Risch HA, Yu 
H, Jia W. Plasma metabolite biomarkers for the detection 
of pancreatic cancer. J Proteome Res. 2015; 14:1195–202. 
https://doi.org/10.1021/pr501135f.
83. Ritchie SA, Chitou B, Zheng Q, Jayasinghe D, Jin W, 
Mochizuki A, Goodenowe DB. Pancreatic cancer serum 
biomarker PC-594: Diagnostic performance and comparison 
to CA19–9. World J Gastroenterol. 2015; 21:6604–12. 
https://doi.org/10.3748/wjg.v21.i21.6604.
84. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown 
DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M. 
Serum markers in patients with resectable pancreatic 
adenocarcinoma: macrophage inhibitory cytokine 1 versus 
CA19–9. Clin Cancer Res. 2006; 12:442–6. https://doi.
org/10.1158/1078-0432.CCR-05-0564.
85. Tesiram YA, Lerner M, Stewart C, Njoku C, Brackett DJ. 
Utility of nuclear magnetic resonance spectroscopy for 
pancreatic cancer studies. Pancreas. 2012; 41:474–80. 
https://doi.org/10.1097/MPA.0b013e31822a708c.
86. Urayama S, Zou W, Brooks K, Tolstikov V. Comprehensive 
mass spectrometry based metabolic profiling of blood 
plasma reveals potent discriminatory classifiers of 
pancreatic cancer. Rapid Commun Mass Spectrom. 2010; 
24:613–20. https://doi.org/10.1002/rcm.4420.
87. Ritchie SA, Akita H, Takemasa I, Eguchi H, Pastural E, 
Nagano H, Monden M, Doki Y, Mori M, Jin W, Sajobi TT, 
Jayasinghe D, Chitou B, et al. Metabolic system alterations 
in pancreatic cancer patient serum: potential for early 
detection. BMC Cancer. 2013; 13:416. https://doi.
org/10.1186/1471-2407-13-416.
